Compositions and methods for treating age-related macular degeneration
AssigneesUniversity of Virginia Patent Foundation, Tufts Medical Center, Inc.
InventorsPaul Andrew Yates, Elias Reichel, Ashton Leone
Life of this patent
Estimating the term…
Abstract
Provided are chemically modified tetracycline (CMT) derivatives for the treatment of non-exudative macular degeneration. The CMT derivatives lack antimicrobial activity, include a phenol ring, and a chemical structure sufficient to chelate Zn2+. Methods of inhibiting and/or minimizing inflammation in a subject, including administering to the subject a dose of a CMT derivative, are also provided. Methods of treating non-exudative age-related macular degeneration (AMD) are provided.
Claims7
A method of treating non-exudative age-related macular degeneration (AMD) in a subject, the method comprising:
- providing a subject susceptible to and/or suffering from non-exudative AMD;
- and
- administering doxycycline to the subject, wherein the doxycycline is administered at a dose of about 100 mg per day, at a dose of about 40 mg per day, or at a dose of less than about 40 mg per day.
Dependencies are inferred from the claim text.